Indivior Plc (INDV)

Indivior PLC (NASDAQ:INDV) is a pharmaceutical company specializing in treatments for opioid use disorder (OUD), with its core products SUBLOCADE, a once-monthly buprenorphine injection, and SUBOXONE ...

Spending on healthcare in the US is predicted to hit $5.3 trillion this year, making it one of the largest in the world.

In an updated report last week, Indivior PLC (NASDAQ:INDV) said that it swung to a net income of $18 million in the second quarter of the year from a $97 million net loss in the same period last year...

Operator: Good day and thank you for standing by. Welcome to the Indivior Second Quarter 2025 Results Conference Call and Webcast.

Indivior PLC (NASDAQ:INDV) announced in its updated report that it swung to a net income of $18 million in the second quarter of the year from a $97 million net loss in the same period last year.

Indivior PLC (NASDAQ:INDV) is a pharmaceutical company focused on opioid addiction treatment, particularly through its flagship product SUBLOCADE, a monthly buprenorphine injection.

On July 1, Alan McKnight, the CIO at Regions Wealth Management, appeared on CNBC to explain how his biggest worry is currently centered around uncertainty, which he believes leads to volatility.

Howard Marks is an American billionaire and the co-chairman and founder of Oaktree Capital, a hedge fund located in Los Angeles, California, USA.

Emily Field, Head of European Pharma Research at Barclays, spoke on CNBC on February 20 about the performance of obesity medications, the effects of US tariffs, and the dynamics of the pharmaceutical ...